ID   WT1_HUMAN               Reviewed;         449 AA.
AC   P19544; A8K6S1; B3KSA5; Q15881; Q16256; Q16575; Q4VXV4; Q4VXV5; Q4VXV6;
AC   Q8IYZ5;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 2.
DT   18-JUN-2025, entry version 266.
DE   RecName: Full=Wilms tumor protein;
DE   AltName: Full=WT33;
GN   Name=WT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RC   TISSUE=Fetal kidney;
RX   PubMed=2154702; DOI=10.1038/343774a0;
RA   Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H., Bruns G.A.P.;
RT   "Homozygous deletion in Wilms tumours of a zinc-finger gene identified by
RT   chromosome jumping.";
RL   Nature 343:774-778(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1; 2;
RP   3 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=1658787; DOI=10.1073/pnas.88.21.9618;
RA   Haber D.A., Sohn R.L., Buckler A.J., Pelletier J., Call K.M., Housman D.E.;
RT   "Alternative splicing and genomic structure of the Wilms tumor gene WT1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9618-9622(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 4).
RX   PubMed=1572653; DOI=10.1016/0888-7543(92)90313-h;
RA   Gessler M., Konig A., Bruns G.A.P.;
RT   "The genomic organization and expression of the WT1 gene.";
RL   Genomics 12:807-813(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 9).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 1).
RG   NIEHS SNPs program;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-449 (ISOFORM 2).
RX   PubMed=2154335; DOI=10.1016/0092-8674(90)90601-a;
RA   Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A.,
RA   Rose E.A., Kral A., Yeger H., Lewis W.H., Jones C., Housman D.E.;
RT   "Isolation and characterization of a zinc finger polypeptide gene at the
RT   human chromosome 11 Wilms' tumor locus.";
RL   Cell 60:509-520(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 301-449 (ISOFORMS 2/4/6), AND FUNCTION.
RC   TISSUE=Fetal kidney;
RX   PubMed=7862533; DOI=10.1093/nar/23.2.277;
RA   Hamilton T.B., Barilla K.C., Romaniuk P.J.;
RT   "High affinity binding sites for the Wilms' tumour suppressor protein
RT   WT1.";
RL   Nucleic Acids Res. 23:277-284(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 385-405, AND VARIANTS DDS.
RX   PubMed=1655284; DOI=10.1016/0092-8674(91)90194-4;
RA   Pelletier J., Bruening W., Kashtan C.E., Mauer S.M., Manivel J.C.,
RA   Striegel J.E., Houghton D.C., Junien C., Habib R., Fouser L., Fine R.N.,
RA   Silverman B.L., Haber D.A., Housman D.E.;
RT   "Germline mutations in the Wilms' tumor suppressor gene are associated with
RT   abnormal urogenital development in Denys-Drash syndrome.";
RL   Cell 67:437-447(1991).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 385-405, AND VARIANTS DDS TYR-330;
RP   PRO-394 AND TRP-394.
RX   PubMed=1302008; DOI=10.1038/ng0592-144;
RA   Bruening W., Bardeesy N., Silverman B.L., Cohn R.A., Machin G.A.,
RA   Aronson A.J., Housman D., Pelletier J.;
RT   "Germline intronic and exonic mutations in the Wilms' tumour gene (WT1)
RT   affecting urogenital development.";
RL   Nat. Genet. 1:144-148(1992).
RN   [13]
RP   IDENTIFICATION OF START CODON, AND ALTERNATIVE SPLICING.
RX   PubMed=1671709; DOI=10.1128/mcb.11.3.1707-1712.1991;
RA   Buckler A.J., Pelletier J., Haber D.A., Glaser T., Housman D.E.;
RT   "Isolation, characterization, and expression of the murine Wilms' tumor
RT   gene (WT1) during kidney development.";
RL   Mol. Cell. Biol. 11:1707-1712(1991).
RN   [14]
RP   RNA EDITING OF POSITION 281.
RX   PubMed=7926762; DOI=10.1101/gad.8.6.720;
RA   Sharma P.M., Bowman M., Madden S.L., Rauscher F.J. III, Sukumar S.;
RT   "RNA editing in the Wilms' tumor susceptibility gene, WT1.";
RL   Genes Dev. 8:720-731(1994).
RN   [15]
RP   ALTERNATIVE INITIATION, AND ALTERNATIVE SPLICING (ISOFORMS 7 AND 8).
RX   PubMed=8621495; DOI=10.1074/jbc.271.15.8646;
RA   Bruening W., Pelletier J.;
RT   "A non-AUG translational initiation event generates novel WT1 isoforms.";
RL   J. Biol. Chem. 271:8646-8654(1996).
RN   [16]
RP   INTERACTION WITH WTAP.
RX   PubMed=11001926; DOI=10.1093/oxfordjournals.hmg.a018914;
RA   Little N.A., Hastie N.D., Davies R.C.;
RT   "Identification of WTAP, a novel Wilms' tumour 1-associating protein.";
RL   Hum. Mol. Genet. 9:2231-2239(2000).
RN   [17]
RP   INTERACTION WITH ZNF224.
RX   PubMed=12239212; DOI=10.1074/jbc.m205667200;
RA   Lee T.H., Lwu S., Kim J., Pelletier J.;
RT   "Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2,
RT   a novel transcriptional repressor.";
RL   J. Biol. Chem. 277:44826-44837(2002).
RN   [18]
RP   INTERACTION WITH SRY.
RX   PubMed=12970737; DOI=10.1038/sj.onc.1206717;
RA   Matsuzawa-Watanabe Y., Inoue J., Semba K.;
RT   "Transcriptional activity of testis-determining factor SRY is modulated by
RT   the Wilms' tumor 1 gene product, WT1.";
RL   Oncogene 22:7900-7904(2003).
RN   [19]
RP   REVIEW.
RX   PubMed=1313285;
RA   Haber D.A., Buckler A.J.;
RT   "WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.";
RL   New Biol. 4:97-106(1992).
RN   [20]
RP   REVIEW.
RX   PubMed=8393820; DOI=10.1096/fasebj.7.10.8393820;
RA   Rauscher F.J. III;
RT   "The WT1 Wilms tumor gene product: a developmentally regulated
RT   transcription factor in the kidney that functions as a tumor suppressor.";
RL   FASEB J. 7:896-903(1993).
RN   [21]
RP   INVOLVEMENT IN WILMS TUMOR.
RX   PubMed=1654525; DOI=10.1038/353431a0;
RA   Pelletier J., Bruening W., Li F.P., Haber D.A., Glaser T., Housman D.E.;
RT   "WT1 mutations contribute to abnormal genital system development and
RT   hereditary Wilms' tumour.";
RL   Nature 353:431-434(1991).
RN   [22]
RP   REVIEW.
RX   PubMed=17361230; DOI=10.1038/sj.leu.2404624;
RA   Yang L., Han Y., Suarez Saiz F., Minden M.D.;
RT   "A tumor suppressor and oncogene: the WT1 story.";
RL   Leukemia 21:868-876(2007).
RN   [23]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-73 AND LYS-177, AND SUMOYLATION AT
RP   LYS-73 AND LYS-177.
RX   PubMed=15520190; DOI=10.1158/0008-5472.can-04-1502;
RA   Smolen G.A., Vassileva M.T., Wells J., Matunis M.J., Haber D.A.;
RT   "SUMO-1 modification of the Wilms' tumor suppressor WT1.";
RL   Cancer Res. 64:7846-7851(2004).
RN   [24]
RP   INTERACTION WITH RBM4, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=16934801; DOI=10.1016/j.yexcr.2006.07.008;
RA   Markus M.A., Heinrich B., Raitskin O., Adams D.J., Mangs H., Goy C.,
RA   Ladomery M., Sperling R., Stamm S., Morris B.J.;
RT   "WT1 interacts with the splicing protein RBM4 and regulates its ability to
RT   modulate alternative splicing in vivo.";
RL   Exp. Cell Res. 312:3379-3388(2006).
RN   [25]
RP   FUNCTION, AND MUTAGENESIS OF HIS-343; ARG-366; ARG-372; ARG-394 AND
RP   HIS-434.
RX   PubMed=19123921; DOI=10.1021/bi801586a;
RA   Weiss T.C., Romaniuk P.J.;
RT   "Contribution of individual amino acids to the RNA binding activity of the
RT   Wilms' tumor suppressor protein WT1.";
RL   Biochemistry 48:148-155(2009).
RN   [26]
RP   INTERACTION WITH AMER1, AND FUNCTION.
RX   PubMed=19416806; DOI=10.1073/pnas.0811349106;
RA   Rivera M.N., Kim W.J., Wells J., Stone A., Burger A., Coffman E.J.,
RA   Zhang J., Haber D.A.;
RT   "The tumor suppressor WTX shuttles to the nucleus and modulates WT1
RT   activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8338-8343(2009).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-444, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   9AATAD MOTIF.
RX   PubMed=31375868; DOI=10.1007/s00018-019-03251-w;
RA   Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.;
RT   "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with
RT   valines and intron reservoirs.";
RL   Cell. Mol. Life Sci. 77:1793-1810(2020).
RN   [29]
RP   STRUCTURE BY NMR OF 381-407 IN COMPLEX WITH ZINC IONS.
RX   PubMed=15518539; DOI=10.1021/bi0491999;
RA   Lachenmann M.J., Ladbury J.E., Dong J., Huang K., Carey P., Weiss M.A.;
RT   "Why zinc fingers prefer zinc: ligand-field symmetry and the hidden
RT   thermodynamics of metal ion selectivity.";
RL   Biochemistry 43:13910-13925(2004).
RN   [30]
RP   STRUCTURE BY NMR OF 318-438 IN COMPLEX WITH DNA AND ZINC IONS (ISOFORM 4),
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 318-438 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND FUNCTION.
RX   PubMed=17716689; DOI=10.1016/j.jmb.2007.07.017;
RA   Stoll R., Lee B.M., Debler E.W., Laity J.H., Wilson I.A., Dyson H.J.,
RA   Wright P.E.;
RT   "Structure of the Wilms tumor suppressor protein zinc finger domain bound
RT   to DNA.";
RL   J. Mol. Biol. 372:1227-1245(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 350-440 IN COMPLEX WITH ZINC AND
RP   TARGET DNA, FUNCTION, AND DOMAIN.
RX   PubMed=25258363; DOI=10.1101/gad.250746.114;
RA   Hashimoto H., Olanrewaju Y.O., Zheng Y., Wilson G.G., Zhang X., Cheng X.;
RT   "Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA
RT   sequence.";
RL   Genes Dev. 28:2304-2313(2014).
RN   [32]
RP   VARIANT WT1 CYS-366.
RX   PubMed=1317572; DOI=10.1073/pnas.89.11.4791;
RA   Little M.H., Prosser J., Condie A., Smith P.J., van Heyningen V.,
RA   Hastie N.D.;
RT   "Zinc finger point mutations within the WT1 gene in Wilms tumor patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4791-4795(1992).
RN   [33]
RP   VARIANTS DDS.
RX   PubMed=1338906; DOI=10.1093/hmg/1.5.301;
RA   Baird P.N., Santos A., Groves N., Jadresic L., Cowell J.K.;
RT   "Constitutional mutations in the WT1 gene in patients with Denys-Drash
RT   syndrome.";
RL   Hum. Mol. Genet. 1:301-305(1992).
RN   [34]
RP   VARIANTS DDS.
RX   PubMed=8388765; DOI=10.1093/hmg/2.3.259;
RA   Little M.H., Williamson K.A., Mannens M., Kelsey A., Gosden C.,
RA   Hastie N.D., van Heyningen V.;
RT   "Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a
RT   dominant-negative fashion.";
RL   Hum. Mol. Genet. 2:259-264(1993).
RN   [35]
RP   VARIANT DDS TYR-401.
RX   PubMed=8111391; DOI=10.1093/hmg/2.12.2193;
RA   Baird P.N., Cowell J.K.;
RT   "A novel zinc finger mutation in a patient with Denys-Drash syndrome.";
RL   Hum. Mol. Genet. 2:2193-2194(1993).
RN   [36]
RP   VARIANTS DDS TRP-394 AND PRO-398.
RX   PubMed=8295405; DOI=10.1007/bf00714282;
RA   Tsuda M., Sakiyama T., Kitagawa T., Watanabe S., Watanabe T., Takahashi S.,
RA   Kawaguchi H., Ito K.;
RT   "Molecular analysis of two Japanese cases of Denys-Drash syndrome.";
RL   J. Inherit. Metab. Dis. 16:876-880(1993).
RN   [37]
RP   VARIANTS DDS TYR-360 AND TRP-394.
RX   PubMed=8411073; DOI=10.1136/jmg.30.9.767;
RA   Clarkson P.A., Davies H.R., Williams D.M., Chaudhary R., Hughes I.A.,
RA   Patterson M.N.;
RT   "Mutational screening of the Wilms's tumour gene, WT1, in males with
RT   genital abnormalities.";
RL   J. Med. Genet. 30:767-772(1993).
RN   [38]
RP   VARIANT GLY-273, AND INVOLVEMENT IN MESOM.
RX   PubMed=8401592; DOI=10.1038/ng0893-415;
RA   Park S., Schalling M., Bernard A., Maheswaran S., Shipley G.C., Roberts D.,
RA   Fletcher J., Shipman R., Rheinwald J., Demetri G., Griffin J., Minden M.,
RA   Housman D.E., Haber D.A.;
RT   "The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues
RT   and mutated in a human mesothelioma.";
RL   Nat. Genet. 4:415-420(1993).
RN   [39]
RP   VARIANT DDS ARG-377.
RX   PubMed=8112732; DOI=10.1007/bf00210593;
RA   Nordenskjold A., Friedman E., Anvret M.;
RT   "WT1 mutations in patients with Denys-Drash syndrome: a novel mutation in
RT   exon 8 and paternal allele origin.";
RL   Hum. Genet. 93:115-120(1994).
RN   [40]
RP   VARIANT DDS LEU-366.
RX   PubMed=8741319; DOI=10.1111/j.1442-200x.1996.tb03483.x;
RA   Tsuda M., Sakiyama T., Owada M., Chiba Y.;
RT   "A newly identified exonic mutation of the WT1 gene in a patient with
RT   Denys-Drash syndrome.";
RL   Acta Paediatr. Jpn. Overseas Ed. 38:265-266(1996).
RN   [41]
RP   VARIANT DDS TYR-373.
RX   PubMed=8956030; DOI=10.1159/000154374;
RA   Ghahremani M., Chan C.B., Bistritzer T., Aladjem M.M., Tieder M.,
RA   Pelletier J.;
RT   "A novel mutation H373Y in the Wilms' tumor suppressor gene, WT1,
RT   associated with Denys-Drash syndrome.";
RL   Hum. Hered. 46:336-338(1996).
RN   [42]
RP   VARIANTS WT1 SER-181 AND ALA-253.
RX   PubMed=9108089; DOI=10.1073/pnas.94.8.3972;
RA   Schumacher V., Schneider S., Figge A., Wildhardt G., Harms D., Schmidt D.,
RA   Weirich A., Ludwig R., Royer-Pokora B.;
RT   "Correlation of germ-line mutations and two-hit inactivation of the WT1
RT   gene with Wilms tumors of stromal-predominant histology.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3972-3977(1997).
RN   [43]
RP   VARIANTS NPHS4 TYR-377; LEU-383 AND ASN-396, VARIANTS DDS CYS-366; GLN-394;
RP   TRP-394 AND PRO-398, AND VARIANT WT1 ASN-223.
RX   PubMed=9529364; DOI=10.1086/301806;
RA   Jeanpierre C., Denamur E., Henry I., Cabanis M.-O., Luce S., Cecille A.,
RA   Elion J., Peuchmaur M., Loirat C., Niaudet P., Gubler M.-C., Junien C.;
RT   "Identification of constitutional WT1 mutations, in patients with isolated
RT   diffuse mesangial sclerosis, and analysis of genotype/phenotype
RT   correlations by use of a computerized mutation database.";
RL   Am. J. Hum. Genet. 62:824-833(1998).
RN   [44]
RP   VARIANTS DDS TYR-355; HIS-366 AND ARG-385.
RX   PubMed=9475094; DOI=10.1136/jmg.35.1.45;
RA   Kikuchi H., Takata A., Akasaka Y., Fukuzawa R., Yoneyama H., Kurosawa Y.,
RA   Honda M., Kamiyama Y., Hata J.;
RT   "Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier
RT   syndrome?";
RL   J. Med. Genet. 35:45-48(1998).
RN   [45]
RP   VARIANTS NPHS4 LEU-364; HIS-366; CYS-379; ARG-385; GLN-394; TRP-394 AND
RP   ASN-396.
RX   PubMed=9607189; DOI=10.1046/j.1523-1755.1998.00948.x;
RA   Schumacher V., Schaerer K., Wuehl E., Altrogge H., Bonzel K.-E.,
RA   Guschmann M., Neuhaus T.J., Pollastro R.M., Kuwertz-Broeking E., Bulla M.,
RA   Tondera A.-M., Mundel P., Helmchen U., Waldherr R., Weirich A.,
RA   Royer-Pokora B.;
RT   "Spectrum of early onset nephrotic syndrome associated with WT1 missense
RT   mutations.";
RL   Kidney Int. 53:1594-1600(1998).
RN   [46]
RP   VARIANT FS LEU-392.
RX   PubMed=10571943;
RX   DOI=10.1002/(sici)1098-1004(199912)14:6<466::aid-humu4>3.0.co;2-6;
RA   Kohsaka T., Tagawa M., Takekoshi Y., Yanagisawa H., Tadokoro K., Yamada M.;
RT   "Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms,
RT   are also responsible for Frasier syndrome.";
RL   Hum. Mutat. 14:466-470(1999).
RN   [47]
RP   VARIANT DDS TYR-396.
RX   PubMed=10738002;
RX   DOI=10.1002/(sici)1098-1004(200004)15:4<389::aid-humu29>3.0.co;2-e;
RA   Little M., Carman G., Donaldson E.;
RT   "Novel WT1 exon 9 mutation (D396Y) in a patient with early onset Denys
RT   Drash syndrome.";
RL   Hum. Mutat. 15:389-389(2000).
RN   [48]
RP   VARIANTS DDS ARG-342; TYR-355; HIS-366; ARG-385; PHE-388; TRP-394 AND
RP   ASN-396, AND VARIANT NPHS4 GLN-312.
RX   PubMed=11182928; DOI=10.1136/jmg.37.9.698;
RA   Takata A., Kikuchi H., Fukuzawa R., Ito S., Honda M., Hata J.;
RT   "Constitutional WT1 correlate with clinical features in children with
RT   progressive nephropathy.";
RL   J. Med. Genet. 37:698-701(2000).
RN   [49]
RP   VARIANT DDS PRO-369.
RX   PubMed=10799199; DOI=10.1097/00005392-200006000-00052;
RA   Ohta S., Ozawa T., Izumino K., Sakuragawa N., Fuse H.;
RT   "A novel missense mutation of the WT1 gene causing Denys-Drash syndrome
RT   with exceptionally mild renal manifestations.";
RL   J. Urol. 163:1857-1858(2000).
RN   [50]
RP   VARIANT DDS TYR-388.
RX   PubMed=11519891; DOI=10.1007/s004670100626;
RA   Swiatecka-Urban A., Mokrzycki M.H., Kaskel F., Da Silva F., Denamur E.;
RT   "Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.";
RL   Pediatr. Nephrol. 16:627-630(2001).
RN   [51]
RP   VARIANTS WT1 SER-181; GLY-355; CYS-366; HIS-366; GLN-373; TRP-394 AND
RP   LEU-394.
RX   PubMed=15150775; DOI=10.1002/ajmg.a.30015;
RA   Royer-Pokora B., Beier M., Henzler M., Alam R., Schumacher V., Weirich A.,
RA   Huff V.;
RT   "Twenty-four new cases of WT1 germline mutations and review of the
RT   literature: genotype/phenotype correlations for Wilms tumor development.";
RL   Am. J. Med. Genet. A 127:249-257(2004).
RN   [52]
RP   VARIANT THR-131.
RX   PubMed=15266301; DOI=10.1038/sj.ejhg.5201232;
RA   Wang Y., Li Q., Xu J., Liu Q., Wang W., Lin Y., Ma F., Chen T., Li S.,
RA   Shen Y.;
RT   "Mutation analysis of five candidate genes in Chinese patients with
RT   hypospadias.";
RL   Eur. J. Hum. Genet. 12:706-712(2004).
RN   [53]
RP   VARIANTS NPHS4 ARG-388 AND PRO-397.
RX   PubMed=15253707; DOI=10.1111/j.1523-1755.2004.00775.x;
RG   Members of the APN study group;
RA   Ruf R.G., Schultheiss M., Lichtenberger A., Karle S.M., Zalewski I.,
RA   Mucha B., Everding A.S., Neuhaus T., Patzer L., Plank C., Haas J.P.,
RA   Ozaltin F., Imm A., Fuchshuber A., Bakkaloglu A., Hildebrandt F.;
RT   "Prevalence of WT1 mutations in a large cohort of patients with steroid-
RT   resistant and steroid-sensitive nephrotic syndrome.";
RL   Kidney Int. 66:564-570(2004).
RN   [54]
RP   VARIANT DDS ARG-405.
RX   PubMed=15349765; DOI=10.1007/s00467-004-1564-3;
RA   Hu M., Craig J., Howard N., Kan A., Chaitow J., Little D., Alexander S.I.;
RT   "A novel mutation of WT1 exon 9 in a patient with Denys-Drash syndrome and
RT   pyloric stenosis.";
RL   Pediatr. Nephrol. 19:1160-1163(2004).
RN   [55]
RP   VARIANTS MEACHS CYS-366 AND TRP-394.
RX   PubMed=17853480; DOI=10.1002/ajmg.a.31924;
RA   Suri M., Kelehan P., O'neill D., Vadeyar S., Grant J., Ahmed S.F.,
RA   Tolmie J., McCann E., Lam W., Smith S., FitzPatrick D., Hastie N.D.,
RA   Reardon W.;
RT   "WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of
RT   the cardiac and diaphragmatic malformations.";
RL   Am. J. Med. Genet. A 143:2312-2320(2007).
RN   [56]
RP   VARIANTS NPHS4 ARG-388; GLN-394; TRP-394 AND PRO-397.
RX   PubMed=20798252; DOI=10.2215/cjn.01190210;
RA   Buescher A.K., Kranz B., Buescher R., Hildebrandt F., Dworniczak B.,
RA   Pennekamp P., Kuwertz-Broeking E., Wingen A.M., John U., Kemper M.,
RA   Monnens L., Hoyer P.F., Weber S., Konrad M.;
RT   "Immunosuppression and renal outcome in congenital and pediatric steroid-
RT   resistant nephrotic syndrome.";
RL   Clin. J. Am. Soc. Nephrol. 5:2075-2084(2010).
CC   -!- FUNCTION: Transcription factor that plays an important role in cellular
CC       development and cell survival (PubMed:7862533). Recognizes and binds to
CC       the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:17716689, PubMed:25258363,
CC       PubMed:7862533). Regulates the expression of numerous target genes,
CC       including EPO. Plays an essential role for development of the
CC       urogenital system. It has a tumor suppressor as well as an oncogenic
CC       role in tumor formation. Function may be isoform-specific: isoforms
CC       lacking the KTS motif may act as transcription factors
CC       (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and
CC       play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1
CC       has lower affinity for DNA, and can bind RNA (PubMed:19123921).
CC       {ECO:0000269|PubMed:15520190, ECO:0000269|PubMed:16934801,
CC       ECO:0000269|PubMed:17716689, ECO:0000269|PubMed:19123921,
CC       ECO:0000269|PubMed:19416806, ECO:0000269|PubMed:25258363,
CC       ECO:0000269|PubMed:7862533}.
CC   -!- SUBUNIT: Homodimer. Interacts with WTIP. Interacts with actively
CC       translating polysomes. Detected in nuclear ribonucleoprotein (mRNP)
CC       particles. Interacts with HNRNPU via the zinc-finger region. Interacts
CC       with U2AF2. Interacts with CITED2 (By similarity). Interacts with
CC       ZNF224 via the zinc-finger region. Interacts with WTAP and SRY.
CC       Interacts with AMER1. Interacts with RBM4. {ECO:0000250,
CC       ECO:0000269|PubMed:11001926, ECO:0000269|PubMed:12239212,
CC       ECO:0000269|PubMed:12970737, ECO:0000269|PubMed:15518539,
CC       ECO:0000269|PubMed:16934801, ECO:0000269|PubMed:17716689,
CC       ECO:0000269|PubMed:19416806}.
CC   -!- INTERACTION:
CC       P19544; Q92997: DVL3; NbExp=3; IntAct=EBI-2320534, EBI-739789;
CC       P19544; Q6A162: KRT40; NbExp=4; IntAct=EBI-2320534, EBI-10171697;
CC       P19544; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2320534, EBI-10171774;
CC       P19544; Q6N021: TET2; NbExp=9; IntAct=EBI-2320534, EBI-310727;
CC       P19544-6; P05067: APP; NbExp=3; IntAct=EBI-11745701, EBI-77613;
CC       P19544-6; O14503: BHLHE40; NbExp=3; IntAct=EBI-11745701, EBI-711810;
CC       P19544-6; P28329-3: CHAT; NbExp=3; IntAct=EBI-11745701, EBI-25837549;
CC       P19544-6; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11745701, EBI-3867333;
CC       P19544-6; P25685: DNAJB1; NbExp=3; IntAct=EBI-11745701, EBI-357034;
CC       P19544-6; P22607: FGFR3; NbExp=3; IntAct=EBI-11745701, EBI-348399;
CC       P19544-6; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-11745701, EBI-2549423;
CC       P19544-6; P01112: HRAS; NbExp=3; IntAct=EBI-11745701, EBI-350145;
CC       P19544-6; O15397: IPO8; NbExp=3; IntAct=EBI-11745701, EBI-358808;
CC       P19544-6; P60371: KRTAP10-6; NbExp=3; IntAct=EBI-11745701, EBI-12012928;
CC       P19544-6; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-11745701, EBI-10172290;
CC       P19544-6; Q9H4L5: OSBPL3; NbExp=3; IntAct=EBI-11745701, EBI-1051317;
CC       P19544-6; P16284: PECAM1; NbExp=3; IntAct=EBI-11745701, EBI-716404;
CC       P19544-6; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-11745701, EBI-79165;
CC       P19544-6; Q13501: SQSTM1; NbExp=3; IntAct=EBI-11745701, EBI-307104;
CC       P19544-6; P37173: TGFBR2; NbExp=3; IntAct=EBI-11745701, EBI-296151;
CC       P19544-6; Q15007: WTAP; NbExp=3; IntAct=EBI-11745701, EBI-751647;
CC       P19544-6; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-11745701, EBI-527853;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15520190}. Nucleus,
CC       nucleolus. Cytoplasm {ECO:0000250}. Note=Isoforms lacking the KTS motif
CC       have a diffuse nuclear location (PubMed:15520190). Shuttles between
CC       nucleus and cytoplasm. {ECO:0000250, ECO:0000269|PubMed:15520190}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus speckle
CC       {ECO:0000269|PubMed:15520190}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:15520190}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC       Name=1;
CC         IsoId=P19544-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19544-2; Sequence=VSP_006866, VSP_006867;
CC       Name=3;
CC         IsoId=P19544-3; Sequence=VSP_006866;
CC       Name=4;
CC         IsoId=P19544-4; Sequence=VSP_006867;
CC       Name=6;
CC         IsoId=P19544-6; Sequence=VSP_037582, VSP_037584, VSP_006867;
CC       Name=7;
CC         IsoId=P19544-7; Sequence=VSP_037583;
CC       Name=8;
CC         IsoId=P19544-8; Sequence=VSP_037583, VSP_006866;
CC       Name=9;
CC         IsoId=P19544-9; Sequence=VSP_037582, VSP_037584, VSP_006866;
CC   -!- TISSUE SPECIFICITY: Expressed in the kidney and a subset of
CC       hematopoietic cells.
CC   -!- DOMAIN: Binds to DNA motifs with the sequence 5'-GCG(T/G)GGGCG-3' via
CC       its C2H2-type zinc fingers. Starting from the N-terminus, the second
CC       zinc finger binds to the 3'-GCG motif, the middle zinc finger interacts
CC       with the central TGG motif, and the C-terminal zinc finger binds to the
CC       5'-GCG motif. Binds double-stranded target DNA, irrespective of the
CC       cytosine methylation status. Has reduced affinity for target DNA where
CC       the cytosines have been oxidized to 5-hydroxymethylcytosine, 5-
CC       formylcytosine or 5-carboxylcytosine. {ECO:0000269|PubMed:25258363}.
CC   -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:31375868}.
CC   -!- RNA EDITING: Modified_positions=281 {ECO:0000269|PubMed:7926762};
CC       Note=Partially edited.;
CC   -!- DISEASE: Frasier syndrome (FS) [MIM:136680]: Characterized by a slowly
CC       progressing nephropathy leading to renal failure in adolescence or
CC       early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for
CC       histological findings of the kidneys, focal glomerular sclerosis is
CC       often observed. There is phenotypic overlap with Denys-Drash syndrome.
CC       Inheritance is autosomal dominant. {ECO:0000269|PubMed:10571943}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Wilms tumor 1 (WT1) [MIM:194070]: Embryonal malignancy of the
CC       kidney that affects approximately 1 in 10'000 infants and young
CC       children. It occurs both in sporadic and hereditary forms.
CC       {ECO:0000269|PubMed:1317572, ECO:0000269|PubMed:15150775,
CC       ECO:0000269|PubMed:9108089, ECO:0000269|PubMed:9529364}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Denys-Drash syndrome (DDS) [MIM:194080]: Typical nephropathy
CC       characterized by diffuse mesangial sclerosis, genital abnormalities,
CC       and/or Wilms tumor. There is phenotypic overlap with WAGR syndrome and
CC       Frasier syndrome. Inheritance is autosomal dominant, but most cases are
CC       sporadic. {ECO:0000269|PubMed:10738002, ECO:0000269|PubMed:10799199,
CC       ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:11519891,
CC       ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:1338906,
CC       ECO:0000269|PubMed:15349765, ECO:0000269|PubMed:1655284,
CC       ECO:0000269|PubMed:8111391, ECO:0000269|PubMed:8112732,
CC       ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8388765,
CC       ECO:0000269|PubMed:8411073, ECO:0000269|PubMed:8741319,
CC       ECO:0000269|PubMed:8956030, ECO:0000269|PubMed:9475094,
CC       ECO:0000269|PubMed:9529364}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Nephrotic syndrome 4 (NPHS4) [MIM:256370]: A form of nephrotic
CC       syndrome, a renal disease clinically characterized by severe
CC       proteinuria, resulting in complications such as hypoalbuminemia,
CC       hyperlipidemia and edema. Kidney biopsies show non-specific histologic
CC       changes such as focal segmental glomerulosclerosis and diffuse
CC       mesangial proliferation. Some affected individuals have an inherited
CC       steroid-resistant form and progress to end-stage renal failure. Most
CC       patients with NPHS4 show diffuse mesangial sclerosis on renal biopsy,
CC       which is a pathologic entity characterized by mesangial matrix
CC       expansion with no mesangial hypercellularity, hypertrophy of the
CC       podocytes, vacuolized podocytes, thickened basement membranes, and
CC       diminished patency of the capillary lumen.
CC       {ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:15253707,
CC       ECO:0000269|PubMed:20798252, ECO:0000269|PubMed:9529364,
CC       ECO:0000269|PubMed:9607189}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Meacham syndrome (MEACHS) [MIM:608978]: Rare sporadically
CC       occurring multiple malformation syndrome characterized by male
CC       pseudohermaphroditism with abnormal internal female genitalia
CC       comprising a uterus and double or septate vagina, complex congenital
CC       heart defect and diaphragmatic abnormalities.
CC       {ECO:0000269|PubMed:17853480}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving WT1 may be a cause of
CC       desmoplastic small round cell tumor (DSRCT). Translocation
CC       t(11;22)(p13;q12) with EWSR1.
CC   -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive
CC       neoplasm of the serosal lining of the chest. It appears as broad sheets
CC       of cells, with some regions containing spindle-shaped, sarcoma-like
CC       cells and other regions showing adenomatous patterns. Pleural
CC       mesotheliomas have been linked to exposure to asbestos.
CC       {ECO:0000269|PubMed:8401592}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Presence of the KTS motif hinders interactions between
CC       DNA and zinc-finger 4.
CC   -!- MISCELLANEOUS: [Isoform 1]: Detected in nucleus speckle, may bind mRNA.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative initiation of
CC       isoform 1. Extended N-terminus. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative initiation of
CC       isoform 1. Extended N-terminus. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the EGR C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB33443.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA35956.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA35956.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC       Sequence=CAC39220.3; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAI95758.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAI95759.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/78/WT1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X51630; CAA35956.1; ALT_SEQ; mRNA.
DR   EMBL; M80232; AAA61299.1; -; Genomic_DNA.
DR   EMBL; M80217; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80218; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80219; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80220; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80221; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80228; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80229; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80231; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; X61631; CAA43819.1; -; Genomic_DNA.
DR   EMBL; X61632; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61633; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61634; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61635; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61636; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61637; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61638; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; AK093168; BAG52667.1; -; mRNA.
DR   EMBL; AK291736; BAF84425.1; -; mRNA.
DR   EMBL; AY245105; AAO61088.1; -; Genomic_DNA.
DR   EMBL; AL049692; CAC39220.3; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95758.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95759.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95760.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68220.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68223.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68224.1; -; Genomic_DNA.
DR   EMBL; BC032861; AAH32861.1; -; mRNA.
DR   EMBL; M30393; AAA36810.1; -; mRNA.
DR   EMBL; S75264; AAB33443.1; ALT_SEQ; mRNA.
DR   EMBL; S61515; AAB20110.1; -; Genomic_DNA.
DR   EMBL; S61522; AAB20111.1; -; Genomic_DNA.
DR   EMBL; S61524; AAB20112.1; -; Genomic_DNA.
DR   EMBL; S60755; AAC60605.1; -; Genomic_DNA.
DR   CCDS; CCDS55750.1; -. [P19544-9]
DR   CCDS; CCDS55751.1; -. [P19544-6]
DR   CCDS; CCDS7878.3; -. [P19544-7]
DR   PIR; A38080; A38080.
DR   RefSeq; NP_000369.3; NM_000378.4.
DR   RefSeq; NP_001185480.1; NM_001198551.2. [P19544-6]
DR   RefSeq; NP_001185481.1; NM_001198552.2. [P19544-9]
DR   RefSeq; NP_001393974.1; NM_001407045.1. [P19544-8]
DR   RefSeq; NP_001415960.1; NM_001429031.1. [P19544-1]
DR   RefSeq; NP_001415961.1; NM_001429032.1. [P19544-4]
DR   RefSeq; NP_001415962.1; NM_001429033.1. [P19544-3]
DR   RefSeq; NP_001415963.1; NM_001429034.1. [P19544-2]
DR   RefSeq; NP_077742.2; NM_024424.3.
DR   RefSeq; NP_077744.3; NM_024426.4. [P19544-7]
DR   PDB; 1XF7; NMR; -; A=381-407.
DR   PDB; 2JP9; NMR; -; A=318-438.
DR   PDB; 2JPA; NMR; -; A=318-438.
DR   PDB; 2PRT; X-ray; 3.15 A; A=318-438.
DR   PDB; 3HPJ; X-ray; 2.00 A; C/F=126-134.
DR   PDB; 3MYJ; X-ray; 1.89 A; C/F=126-134.
DR   PDB; 4R2E; X-ray; 1.84 A; A=350-440.
DR   PDB; 4R2P; X-ray; 1.79 A; A=350-440.
DR   PDB; 4R2Q; X-ray; 1.54 A; A=350-440.
DR   PDB; 4R2R; X-ray; 2.09 A; A=350-440.
DR   PDB; 4R2S; X-ray; 2.49 A; A=350-440.
DR   PDB; 4WUU; X-ray; 3.05 A; C=126-134.
DR   PDB; 5KL2; X-ray; 1.69 A; A=350-440.
DR   PDB; 5KL3; X-ray; 1.45 A; A=350-440.
DR   PDB; 5KL4; X-ray; 1.78 A; A/D=350-440.
DR   PDB; 5KL5; X-ray; 2.29 A; A=350-440.
DR   PDB; 5KL6; X-ray; 1.64 A; A=350-440.
DR   PDB; 5KL7; X-ray; 1.58 A; A=350-440.
DR   PDB; 6B0O; X-ray; 1.55 A; A/D=321-440.
DR   PDB; 6B0P; X-ray; 2.08 A; A/D=321-440.
DR   PDB; 6B0Q; X-ray; 2.79 A; A/D=321-440.
DR   PDB; 6B0R; X-ray; 1.82 A; A/D=321-440.
DR   PDB; 6BLW; X-ray; 1.83 A; A=319-440.
DR   PDB; 6RSY; X-ray; 2.95 A; C/H=126-134.
DR   PDB; 6WLH; NMR; -; A=318-438.
DR   PDB; 7BBG; X-ray; 2.64 A; C=126-134.
DR   PDB; 8ISN; X-ray; 2.48 A; C/F=235-243.
DR   PDBsum; 1XF7; -.
DR   PDBsum; 2JP9; -.
DR   PDBsum; 2JPA; -.
DR   PDBsum; 2PRT; -.
DR   PDBsum; 3HPJ; -.
DR   PDBsum; 3MYJ; -.
DR   PDBsum; 4R2E; -.
DR   PDBsum; 4R2P; -.
DR   PDBsum; 4R2Q; -.
DR   PDBsum; 4R2R; -.
DR   PDBsum; 4R2S; -.
DR   PDBsum; 4WUU; -.
DR   PDBsum; 5KL2; -.
DR   PDBsum; 5KL3; -.
DR   PDBsum; 5KL4; -.
DR   PDBsum; 5KL5; -.
DR   PDBsum; 5KL6; -.
DR   PDBsum; 5KL7; -.
DR   PDBsum; 6B0O; -.
DR   PDBsum; 6B0P; -.
DR   PDBsum; 6B0Q; -.
DR   PDBsum; 6B0R; -.
DR   PDBsum; 6BLW; -.
DR   PDBsum; 6RSY; -.
DR   PDBsum; 6WLH; -.
DR   PDBsum; 7BBG; -.
DR   PDBsum; 8ISN; -.
DR   AlphaFoldDB; P19544; -.
DR   BMRB; P19544; -.
DR   SMR; P19544; -.
DR   BioGRID; 113327; 69.
DR   FunCoup; P19544; 2064.
DR   IntAct; P19544; 68.
DR   MINT; P19544; -.
DR   STRING; 9606.ENSP00000368370; -.
DR   ChEMBL; CHEMBL4662942; -.
DR   MoonProt; P19544; -.
DR   iPTMnet; P19544; -.
DR   PhosphoSitePlus; P19544; -.
DR   BioMuta; WT1; -.
DR   DMDM; 139778; -.
DR   jPOST; P19544; -.
DR   MassIVE; P19544; -.
DR   PaxDb; 9606-ENSP00000331327; -.
DR   PeptideAtlas; P19544; -.
DR   ProteomicsDB; 53673; -. [P19544-1]
DR   ProteomicsDB; 53674; -. [P19544-2]
DR   ProteomicsDB; 53675; -. [P19544-3]
DR   ProteomicsDB; 53676; -. [P19544-4]
DR   ProteomicsDB; 53677; -. [P19544-6]
DR   ProteomicsDB; 53678; -. [P19544-7]
DR   ProteomicsDB; 53679; -. [P19544-8]
DR   ProteomicsDB; 53680; -. [P19544-9]
DR   Pumba; P19544; -.
DR   ABCD; P19544; 1 sequenced antibody.
DR   Antibodypedia; 3523; 1212 antibodies from 45 providers.
DR   DNASU; 7490; -.
DR   Ensembl; ENST00000379079.8; ENSP00000368370.2; ENSG00000184937.17. [P19544-6]
DR   Ensembl; ENST00000452863.10; ENSP00000415516.5; ENSG00000184937.17. [P19544-7]
DR   Ensembl; ENST00000530998.5; ENSP00000435307.1; ENSG00000184937.17. [P19544-9]
DR   Ensembl; ENST00000639563.4; ENSP00000492269.3; ENSG00000184937.17. [P19544-8]
DR   Ensembl; ENST00000850606.1; ENSP00000520894.1; ENSG00000184937.17. [P19544-2]
DR   Ensembl; ENST00000850608.1; ENSP00000520896.1; ENSG00000184937.17. [P19544-4]
DR   Ensembl; ENST00000850609.1; ENSP00000520897.1; ENSG00000184937.17. [P19544-3]
DR   Ensembl; ENST00000850610.1; ENSP00000520898.1; ENSG00000184937.17. [P19544-2]
DR   GeneID; 7490; -.
DR   KEGG; hsa:7490; -.
DR   MANE-Select; ENST00000452863.10; ENSP00000415516.5; NM_024426.6; NP_077744.4. [P19544-7]
DR   UCSC; uc001mtl.3; human. [P19544-1]
DR   AGR; HGNC:12796; -.
DR   CTD; 7490; -.
DR   DisGeNET; 7490; -.
DR   GeneCards; WT1; -.
DR   GeneReviews; WT1; -.
DR   HGNC; HGNC:12796; WT1.
DR   HPA; ENSG00000184937; Tissue enhanced (endometrium, fallopian tube, ovary).
DR   MalaCards; WT1; -.
DR   MIM; 136680; phenotype.
DR   MIM; 156240; phenotype.
DR   MIM; 194070; phenotype.
DR   MIM; 194080; phenotype.
DR   MIM; 256370; phenotype.
DR   MIM; 607102; gene.
DR   MIM; 608978; phenotype.
DR   OpenTargets; ENSG00000184937; -.
DR   Orphanet; 242; 46,XY complete gonadal dysgenesis.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   Orphanet; 220; Denys-Drash syndrome.
DR   Orphanet; 83469; Desmoplastic small round cell tumor.
DR   Orphanet; 347; Frasier syndrome.
DR   Orphanet; 656; Hereditary steroid-resistant nephrotic syndrome.
DR   Orphanet; 3097; Meacham syndrome.
DR   Orphanet; 654; Nephroblastoma.
DR   Orphanet; 893; WAGR syndrome.
DR   VEuPathDB; HostDB:ENSG00000184937; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000156734; -.
DR   InParanoid; P19544; -.
DR   OMA; QARMFTN; -.
DR   OrthoDB; 8922241at2759; -.
DR   PAN-GO; P19544; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P19544; -.
DR   PathwayCommons; P19544; -.
DR   Reactome; R-HSA-9690406; Transcriptional regulation of testis differentiation.
DR   Reactome; R-HSA-9831926; Nephron development.
DR   SignaLink; P19544; -.
DR   SIGNOR; P19544; -.
DR   BioGRID-ORCS; 7490; 23 hits in 1196 CRISPR screens.
DR   CD-CODE; 804901D1; Nuclear speckle.
DR   ChiTaRS; WT1; human.
DR   EvolutionaryTrace; P19544; -.
DR   GeneWiki; WT1; -.
DR   GenomeRNAi; 7490; -.
DR   Pharos; P19544; Tbio.
DR   PRO; PR:P19544; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P19544; protein.
DR   Bgee; ENSG00000184937; Expressed in germinal epithelium of ovary and 128 other cell types or tissues.
DR   ExpressionAtlas; P19544; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0010385; F:double-stranded methylated DNA binding; IDA:UniProtKB.
DR   GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0035802; P:adrenal cortex formation; ISS:UniProtKB.
DR   GO; GO:0030325; P:adrenal gland development; IGI:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IGI:UniProtKB.
DR   GO; GO:0043010; P:camera-type eye development; ISS:UniProtKB.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; ISS:BHF-UCL.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:UniProtKB.
DR   GO; GO:0071371; P:cellular response to gonadotropin stimulus; IDA:UniProtKB.
DR   GO; GO:0060539; P:diaphragm development; ISS:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007281; P:germ cell development; ISS:UniProtKB.
DR   GO; GO:0032836; P:glomerular basement membrane development; IMP:UniProtKB.
DR   GO; GO:0032835; P:glomerulus development; IGI:UniProtKB.
DR   GO; GO:0008406; P:gonad development; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IGI:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IGI:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; ISS:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; ISS:UniProtKB.
DR   GO; GO:0072207; P:metanephric epithelium development; IEP:UniProtKB.
DR   GO; GO:0072075; P:metanephric mesenchyme development; ISS:UniProtKB.
DR   GO; GO:0072284; P:metanephric S-shaped body morphogenesis; IGI:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IGI:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000195; P:negative regulation of female gonad development; ISS:UniProtKB.
DR   GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IMP:ARUK-UCL.
DR   GO; GO:0072302; P:negative regulation of metanephric glomerular mesangial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0072112; P:podocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0060421; P:positive regulation of heart growth; ISS:UniProtKB.
DR   GO; GO:2000020; P:positive regulation of male gonad development; ISS:UniProtKB.
DR   GO; GO:2001076; P:positive regulation of metanephric ureteric bud development; ISS:UniProtKB.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IMP:ARUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0072166; P:posterior mesonephric tubule development; ISS:UniProtKB.
DR   GO; GO:0003156; P:regulation of animal organ formation; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; ISS:UniProtKB.
DR   GO; GO:0007530; P:sex determination; IDA:UniProtKB.
DR   GO; GO:0007356; P:thorax and anterior abdomen determination; ISS:UniProtKB.
DR   GO; GO:0009888; P:tissue development; ISS:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0061032; P:visceral serous pericardium development; IGI:UniProtKB.
DR   FunFam; 3.30.160.60:FF:000018; Krueppel-like factor 15; 1.
DR   FunFam; 3.30.160.60:FF:000228; Wilms tumor 1-KTS isoform; 1.
DR   FunFam; 3.30.160.60:FF:000241; Wilms tumor 1-KTS isoform; 1.
DR   FunFam; 3.30.160.60:FF:000303; Zinc finger protein 41; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 4.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR23235:SF65; KRUEPPEL-LIKE FACTOR 11; 1.
DR   PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1.
DR   Pfam; PF02165; WT1; 1.
DR   Pfam; PF00096; zf-C2H2; 2.
DR   PRINTS; PR00049; WILMSTUMOUR.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
DR   neXtProt; NX_P19544; -.
DR   PharmGKB; PA37395; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   Chromosomal rearrangement; Cytoplasm; Disease variant; DNA-binding;
KW   Isopeptide bond; Metal-binding; Nucleus; Proteomics identification;
KW   Reference proteome; Repeat; RNA editing; RNA-binding; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..449
FT                   /note="Wilms tumor protein"
FT                   /id="PRO_0000047131"
FT   ZN_FING         323..347
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         353..377
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         383..405
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         414..438
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          48..84
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          367..381
FT                   /note="Important for interaction with target DNA"
FT   REGION          393..401
FT                   /note="Important for interaction with target DNA"
FT   MOTIF           236..244
FT                   /note="9aaTAD"
FT                   /evidence="ECO:0000269|PubMed:31375868"
FT   MOTIF           408..410
FT                   /note="KTS motif"
FT   COMPBIAS        54..69
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            424
FT                   /note="Important for interaction with target DNA"
FT   SITE            430
FT                   /note="Important for interaction with target DNA"
FT   CROSSLNK        73
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   CROSSLNK        177
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   CROSSLNK        444
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..144
FT                   /note="Missing (in isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037582"
FT   VAR_SEQ         1
FT                   /note="M -> MDFLLLQDPASTCVPEPASQHTLRSGPGCLQQPEQQGVRDPGGIWAK
FT                   LGAAEASAERLQGRRSRGASGSEPQQM (in isoform 7 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:2154702"
FT                   /id="VSP_037583"
FT   VAR_SEQ         145..147
FT                   /note="RNQ -> MEK (in isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037584"
FT   VAR_SEQ         250..266
FT                   /note="Missing (in isoform 2, isoform 3, isoform 8 and
FT                   isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:2154335"
FT                   /id="VSP_006866"
FT   VAR_SEQ         408..410
FT                   /note="Missing (in isoform 2, isoform 4 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:2154335"
FT                   /id="VSP_006867"
FT   VARIANT         131
FT                   /note="A -> T (in a patient with hypospadias)"
FT                   /evidence="ECO:0000269|PubMed:15266301"
FT                   /id="VAR_043798"
FT   VARIANT         181
FT                   /note="P -> S (in WT1; dbSNP:rs2234584)"
FT                   /evidence="ECO:0000269|PubMed:15150775,
FT                   ECO:0000269|PubMed:9108089"
FT                   /id="VAR_007739"
FT   VARIANT         223
FT                   /note="S -> N (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007740"
FT   VARIANT         253
FT                   /note="G -> A (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:9108089"
FT                   /id="VAR_007741"
FT   VARIANT         273
FT                   /note="S -> G (found in a mesothelioma sample; somatic
FT                   mutation; dbSNP:rs121907908)"
FT                   /evidence="ECO:0000269|PubMed:8401592"
FT                   /id="VAR_007742"
FT   VARIANT         281
FT                   /note="L -> P (in RNA edited version)"
FT                   /id="VAR_058021"
FT   VARIANT         312
FT                   /note="R -> Q (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:11182928"
FT                   /id="VAR_015053"
FT   VARIANT         330
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:1302008"
FT                   /id="VAR_007743"
FT   VARIANT         342
FT                   /note="M -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928"
FT                   /id="VAR_015054"
FT   VARIANT         355
FT                   /note="C -> G (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:15150775"
FT                   /id="VAR_043799"
FT   VARIANT         355
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:9475094"
FT                   /id="VAR_015055"
FT   VARIANT         360
FT                   /note="C -> G (in DDS)"
FT                   /id="VAR_007744"
FT   VARIANT         360
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8411073"
FT                   /id="VAR_043800"
FT   VARIANT         364
FT                   /note="F -> L (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9607189"
FT                   /id="VAR_043801"
FT   VARIANT         366
FT                   /note="R -> C (in WT1, DDS and MEACHS)"
FT                   /evidence="ECO:0000269|PubMed:1317572,
FT                   ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:17853480,
FT                   ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007745"
FT   VARIANT         366
FT                   /note="R -> H (in DDS and WT1)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:9475094,
FT                   ECO:0000269|PubMed:9607189"
FT                   /id="VAR_007746"
FT   VARIANT         366
FT                   /note="R -> L (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8741319"
FT                   /id="VAR_043802"
FT   VARIANT         369
FT                   /note="Q -> P (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:10799199"
FT                   /id="VAR_043803"
FT   VARIANT         373
FT                   /note="H -> Q (in DDS and WT1)"
FT                   /evidence="ECO:0000269|PubMed:15150775"
FT                   /id="VAR_007747"
FT   VARIANT         373
FT                   /note="H -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8956030"
FT                   /id="VAR_015056"
FT   VARIANT         377
FT                   /note="H -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8112732"
FT                   /id="VAR_015057"
FT   VARIANT         377
FT                   /note="H -> Y (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007748"
FT   VARIANT         379
FT                   /note="G -> C (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9607189"
FT                   /id="VAR_043804"
FT   VARIANT         383
FT                   /note="F -> L (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:9529364"
FT                   /id="VAR_007749"
FT   VARIANT         385
FT                   /note="C -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:9475094, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_015058"
FT   VARIANT         388
FT                   /note="C -> F (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11182928"
FT                   /id="VAR_015059"
FT   VARIANT         388
FT                   /note="C -> R (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:15253707,
FT                   ECO:0000269|PubMed:20798252"
FT                   /id="VAR_043805"
FT   VARIANT         388
FT                   /note="C -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:11519891"
FT                   /id="VAR_043806"
FT   VARIANT         392
FT                   /note="F -> L (in FS)"
FT                   /evidence="ECO:0000269|PubMed:10571943"
FT                   /id="VAR_015060"
FT   VARIANT         394
FT                   /note="R -> L (in WT1)"
FT                   /evidence="ECO:0000269|PubMed:15150775"
FT                   /id="VAR_043807"
FT   VARIANT         394
FT                   /note="R -> P (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:1302008"
FT                   /id="VAR_043808"
FT   VARIANT         394
FT                   /note="R -> Q (in DDS and NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:20798252,
FT                   ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_015061"
FT   VARIANT         394
FT                   /note="R -> W (in DDS, WT1, MEACHS and NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:15150775,
FT                   ECO:0000269|PubMed:17853480, ECO:0000269|PubMed:20798252,
FT                   ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8411073,
FT                   ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_007750"
FT   VARIANT         396
FT                   /note="D -> G (in DDS)"
FT                   /id="VAR_007752"
FT   VARIANT         396
FT                   /note="D -> N (in DDS and NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:11182928,
FT                   ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189"
FT                   /id="VAR_007751"
FT   VARIANT         396
FT                   /note="D -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:10738002"
FT                   /id="VAR_043809"
FT   VARIANT         397
FT                   /note="H -> P (in NPHS4)"
FT                   /evidence="ECO:0000269|PubMed:15253707,
FT                   ECO:0000269|PubMed:20798252"
FT                   /id="VAR_043810"
FT   VARIANT         398
FT                   /note="L -> P (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8295405,
FT                   ECO:0000269|PubMed:9529364"
FT                   /id="VAR_015062"
FT   VARIANT         401
FT                   /note="H -> Y (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:8111391"
FT                   /id="VAR_043811"
FT   VARIANT         405
FT                   /note="H -> R (in DDS)"
FT                   /evidence="ECO:0000269|PubMed:15349765"
FT                   /id="VAR_043812"
FT   MUTAGEN         73
FT                   /note="K->R: Abolishes sumoylation; when associated with
FT                   R-177."
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   MUTAGEN         177
FT                   /note="K->R: Abolishes sumoylation; when associated with
FT                   R-77."
FT                   /evidence="ECO:0000269|PubMed:15520190"
FT   MUTAGEN         343
FT                   /note="H->A: Reduced RNA binding."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         366
FT                   /note="R->A: Strongly reduced binding of DNA and RNA."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         372
FT                   /note="R->A: Strongly reduced binding of DNA and RNA."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         394
FT                   /note="R->A,S: Strongly reduced binding of DNA and RNA."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   MUTAGEN         434
FT                   /note="H->A: Reduced RNA binding."
FT                   /evidence="ECO:0000269|PubMed:19123921"
FT   CONFLICT        288
FT                   /note="I -> M (in Ref. 8; AAH32861)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        365
FT                   /note="S -> F (in Ref. 9; AAA36810 and 10; AAB33443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        387
FT                   /note="T -> A (in Ref. 3; CAA43819)"
FT                   /evidence="ECO:0000305"
FT   STRAND          322..324
FT                   /evidence="ECO:0007829|PDB:6B0Q"
FT   TURN            328..330
FT                   /evidence="ECO:0007829|PDB:6B0R"
FT   STRAND          333..336
FT                   /evidence="ECO:0007829|PDB:6B0O"
FT   HELIX           337..348
FT                   /evidence="ECO:0007829|PDB:6B0O"
FT   STRAND          352..354
FT                   /evidence="ECO:0007829|PDB:6WLH"
FT   STRAND          357..359
FT                   /evidence="ECO:0007829|PDB:6B0R"
FT   STRAND          363..366
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   HELIX           367..378
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   TURN            386..388
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   STRAND          391..393
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   HELIX           395..401
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   HELIX           403..406
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   STRAND          418..420
FT                   /evidence="ECO:0007829|PDB:6BLW"
FT   STRAND          424..427
FT                   /evidence="ECO:0007829|PDB:5KL3"
FT   HELIX           428..438
FT                   /evidence="ECO:0007829|PDB:5KL3"
SQ   SEQUENCE   449 AA;  49188 MW;  11C7FA3D485096B2 CRC64;
     MGSDVRDLNA LLPAVPSLGG GGGCALPVSG AAQWAPVLDF APPGASAYGS LGGPAPPPAP
     PPPPPPPPHS FIKQEPSWGG AEPHEEQCLS AFTVHFSGQF TGTAGACRYG PFGPPPPSQA
     SSGQARMFPN APYLPSCLES QPAIRNQGYS TVTFDGTPSY GHTPSHHAAQ FPNHSFKHED
     PMGQQGSLGE QQYSVPPPVY GCHTPTDSCT GSQALLLRTP YSSDNLYQMT SQLECMTWNQ
     MNLGATLKGV AAGSSSSVKW TEGQSNHSTG YESDNHTTPI LCGAQYRIHT HGVFRGIQDV
     RRVPGVAPTL VRSASETSEK RPFMCAYPGC NKRYFKLSHL QMHSRKHTGE KPYQCDFKDC
     ERRFSRSDQL KRHQRRHTGV KPFQCKTCQR KFSRSDHLKT HTRTHTGKTS EKPFSCRWPS
     CQKKFARSDE LVRHHNMHQR NMTKLQLAL
//
